Arrhythmias & electrophysiology
One-Year Outcomes of the MODULAR Antitachycardia Pacing (ATP) Trial: A Novel Leadless Pacemaker in Wireless Communication With a Subcutaneous Implantable Cardioverter Defibrillator
Authors' conclusion
One-year outcomes of the first modular pacing-defibrillator system reveal low system and LP complication rates and good ATP efficacy rates
Study context
- Population
- Patients with ≥1 clinical risk factor for VT not requiring chronic pacing251 completed 12-month follow-up
- Participants
- 297 patients
- Outcome
- LP major complication-free rate (vs performance goal)
Methodological detailsmulticenter, international
- Multicenter
- International
Main finding
As reported in the abstract
LP major complication-free rate
Leadless pacemaker (LP) major complication-free rate (exceeded performance goal)
97.2%
Further findings
Overall LP + S-ICD system-related complication-free rate
- System-related complication-free rate
- 88.5%
Appropriate therapy
- Appropriate tachyarrhythmia therapy (ATP+shock)
- 14.4%
- Appropriate shocks
- 8.5%
ATP efficacy
- ATP successful in terminating ventricular arrhythmia episodes
- 67.3%
Overall therapy burden (ATP+shock)
- Total therapy burden
- 96/100 patient-years
- Shock burden
- 44/100 patient-years
All-cause mortality
- Mortality rate (none related to implant procedure)
- 6%
Safety
ATP-related acceleration of ventricular arrhythmia
- ATP accelerated ventricular arrhythmias (% of episodes)
- 10.1%
Inappropriate tachyarrhythmia therapy
- Inappropriate total tachyarrhythmia therapy
- 9.5%
- Of which shocks
- 8.5%
Original publication
One-Year Outcomes of the MODULAR ATP Trial: A Novel Leadless Pacemaker in Wireless Communication With a Subcutaneous Implantable Cardioverter Defibrillator. Circ Arrhythm Electrophysiol. Published 13 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →